{"id":11458,"date":"2025-05-26T18:28:08","date_gmt":"2025-05-26T16:28:08","guid":{"rendered":"https:\/\/www.kliinikum.ee\/yhendlabor\/?page_id=11458"},"modified":"2026-10-08T13:01:32","modified_gmt":"2026-10-08T11:01:32","slug":"susteemsete-sidekoehaiguste-uuringud","status":"publish","type":"page","link":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/autoimmuunuuringud\/susteemsete-sidekoehaiguste-uuringud\/","title":{"rendered":"Tuumavastase IgG (ANA IgG) paneel (IIF)"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><em>Immuunanal\u00fc\u00fcsi osakond<\/em><\/p>\n\n\n\n<p class=\"has-medium-font-size wp-block-paragraph\"><strong>Anal\u00fc\u00fcsid:<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table is-style-stripes\"><table><tbody><tr><td width=\"1%\"><\/td><td width=\"99%\">ANA IgG (IIF)<\/td><\/tr><tr><td><\/td><td>ANA IgG muster<\/td><\/tr><tr><td><\/td><td>ANA IgG tiiter<\/td><\/tr><tr><td><\/td><td>S\u00fcsteemsete sidekoehaiguste IgG paneel (IB)<\/td><\/tr><tr><td><\/td><td>S\u00fcsteemse skleroosi IgG paneel (IB)<\/td><\/tr><tr><td><\/td><td>M\u00fcosiitide IgG paneel (IB)<\/td><\/tr><tr><td><\/td><td>Maksahaiguste IgG paneel (IB)<\/td><\/tr><tr><td><\/td><td>dsDNA IgG QN<\/td><\/tr><tr><td><\/td><td>Sm IgG QN<\/td><\/tr><tr><td><\/td><td>U1RNP IgG QN<\/td><\/tr><tr><td><\/td><td>SSA\/Ro IgG QN<\/td><\/tr><tr><td><\/td><td>SSB\/La IgG QN<\/td><\/tr><tr><td><\/td><td>Scl70 IgG QN<\/td><\/tr><tr><td><\/td><td>Tsentromeer B IgG QN<\/td><\/tr><tr><td><\/td><td>Jo1 IgG QN<\/td><\/tr><tr><td><\/td><td>AMA M2 IgG QN<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Tuumavastased antikehad (<em>anti-nuclear antibodies<\/em>, ANA)&nbsp; on rakutuuma erinevate komponentide vastu suunatud antikehad, mis on olulised autoimmuunhaiguste diagnostikas. Kliinilises praktikas omavad rohkem t\u00e4htsust IgG t\u00fc\u00fcpi tuumaantikehad (ANA IgG). Eristatakse rakutuuma, ts\u00fctoplasma ja mitootilise raku ANA IgG mustreid, mist\u00f5ttu kasutatakse klassifitseerimisel terminit rakuvastane (<em>anti-cell<\/em>, AC) muster. ANA IgG antikehi esineb v\u00e4ga sageli s\u00fcsteemsete sidekoehaiguste, aga ka autoimmuunsete maksahaiguste korral (vt Tabel 1).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">S\u00fcsteemsed sidekoehaigused moodustavad heterogeense grupi haigusi, mille tekkel m\u00e4ngib juhtivat rolli organismi immuunreaktsioon keha sidekoeliste struktuuride suhtes. Tavaliselt haarab haigus kogu organismi, kahjustades erinevaid kudesid, kuid esineb ka piirdunud sidekoehaiguste vorme. Immuuntolerantsi h\u00e4irumisel organismi enda kudede suhtes aktiveeruvad nii rakulised kui ka humoraalsed immuuns\u00fcsteemi komponendid, mille t\u00f5ttu haaratud kudedes tekib steriilne p\u00f5letik ning haige verre ilmuvad autoantikehad. Paljudel s\u00fcsteemsete sidekoehaiguste vormidel on iseloomulik autoantikehade spekter ning seet\u00f5ttu kasutatakse defineeritud antigeenidega reageerivate autoantikehade m\u00e4\u00e4ramist laialdaselt s\u00fcsteemsete sidekoehaiguste diagnostikas<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">1. <strong>ANA IgG<\/strong> t\u00fc\u00fcpi antikehade m\u00e4\u00e4ramiseks kasutatakse immunofluorestsents-meetodit (IIF) inimese kartsinoomi rakuliinil&nbsp; HEp-2. See ei v\u00f5imalda identifitseerida t\u00e4pset antikeha. Positiivse anal\u00fc\u00fcsitulemuse korral kirjeldatakse vastusena erinevaid ANA mustreid, mille nimetused on kokku lepitud rahvusvaheliselt (<em>International Consensus on ANA Patterns (ICAP<\/em>)) ning mis on Eestis \u00fchtlustatud vastavalt Eesti Laborimeditsiini \u00dchingu autoimmuunuuringute t\u00f6\u00f6r\u00fchma kokkulepetele. ANA IgG mustrid, neile vastavad sihtantigeenid ja seos haigustega on toodud tabelis 3. Positiivse ANA IgG IIF anal\u00fc\u00fcsi korral v\u00e4ljastatakse alati <strong>ANA IgG muster ja ANA IgG tiiter<\/strong> (alates 19.10.2026 ANA IgG tiitrit eraldi lisaanal\u00fc\u00fcsina tellida ei saa).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">NB! ANA IgG paneeli (IIF) tellimisel peab t\u00e4psustama, kas positiivse tulemuse korral soovitakse koheselt ka t\u00e4psustavaid uuringuid (antikehade paneelid ja v\u00f5imalusel antikeha hulga kvantitatiivne m\u00e4\u00e4ramine) v\u00f5i lisaanal\u00fc\u00fcse ei soovita (vt. ANA IgG algoritm autoimmuunhaiguste diagnostikas).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">2. T\u00e4psustavad anal\u00fc\u00fcsid vastavalt <strong>ANA IgG algoritmile.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">2.1 Spetsiifiliste antikehade paneelid <em>immunoblot<\/em>-meetodil. Paneeli valik p\u00f5hineb tuvastatud ANA mustril (vt Tabel 2):<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>S\u00fcsteemsete sidekoehaiguste IgG paneel<\/strong> (U1RNP, Sm, SSA IgG, Ro52 IgG, SSB, Scl70, PM\/Scl, Jo1, tsentromeer B, PCNA, dsDNA, nukleosoom, histoon, Rib P Prot, AMA M2)<\/li>\n\n\n\n<li><strong>S\u00fcsteemse skleroosi IgG paneel<\/strong> (Scl70, tsentromeer A, tsentromeer B, RP11, RP155, fibrillariin, NOR90, Th\/To, PM\/Scl100, PM\/Scl75, Ku, PDGFR, Ro52)<\/li>\n\n\n\n<li><strong>M\u00fcosiitide IgG paneel<\/strong> (Mi2\u03b1, Mi2\u03b2, TIF1\u03b3, MDA5, NXP2, SAE1, Ku, PM\/ScL100, PM\/Scl75, Jo1, SRP, PL7, PL12, EJ, OJ, Ro52)<\/li>\n\n\n\n<li><strong>Maksahaiguste IgG paneel<\/strong> (AMA-M2, AMA M2-3E (BPO), Sp100, PML, gp210, LKM-1, LC-1, SLA\/LP, Ro52 IgG).<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">2.2 Teatud antikehade positiivse tulemuse korral m\u00e4\u00e4ratakse <strong>antikehade hulk.<\/strong> Kvantitatiivselt on v\u00f5imalik m\u00e4\u00e4rata: dsDNA IgG QN, Sm IgG QN, U1RNP IgG QN, SSA IgG QN, SSB IgG QN, Scl70 IgG QN, Tsentromeer B IgG QN, Jo1 IgG QN, AMA M2 IgG QN.<\/p>\n\n\n\n<p class=\"has-medium-font-size wp-block-paragraph\"><strong>Uuritav materjal, selle v\u00f5tmine, saatmine ja s\u00e4ilitamine<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table is-style-stripes\"><table width=\"100%\"><tbody><tr><td width=\"1%\"><\/td><td width=\"15%\"><strong>Katsuti<\/strong><\/td><td width=\"84%\">&nbsp;Geeli ja h\u00fc\u00fcbimisaktivaatoriga katsuti (punane kollase r\u00f5ngaga v\u00f5i kollane kork)<\/td><\/tr><tr><td width=\"1%\"><\/td><td width=\"15%\"><strong>S\u00e4ilivus<\/strong><\/td><td width=\"84%\">&nbsp;Seerum +4 \u00b0C 14 p\u00e4eva<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"has-medium-font-size wp-block-paragraph\"><strong>Anal\u00fc\u00fcsi tegemise aeg<\/strong><\/p>\n\n\n\n<p class=\"has-small-font-size wp-block-paragraph\">ANA IgG, ANA IgG muster ja ANA IgG tiiter: t\u00f6\u00f6p\u00e4eviti<br>Antikehade paneelid: 3 korda n\u00e4dalas<br>Antikehade hulk: 2 korda n\u00e4dalas<\/p>\n\n\n\n<p class=\"has-medium-font-size wp-block-paragraph\"><strong>Anal\u00fc\u00fcsimeetodid<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">ANA IgG, ANA IgG muster ja ANA IgG tiiter: kaudne immunofluorestsentsmeetod (IIF)<br>Antikehade paneelid: <em>immunoblot<\/em>-meetod<br>Antikehade hulk: fluorestsents-ens\u00fc\u00fcmimmuunmeetod (FEIA)<\/p>\n\n\n\n<ol start=\"1\" class=\"wp-block-list\">\n<li><\/li>\n<\/ol>\n\n\n\n<p class=\"has-medium-font-size wp-block-paragraph\"><strong>Vastuse vorm<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table><tbody><tr><td width=\"1%\"><\/td><td width=\"20%\">ANA IgG (IIF)<\/td><td width=\"20%\">Negatiivne<\/td><td width=\"20%\"><\/td><td width=\"39%\">Positiivne<\/td><\/tr><tr><td><\/td><td>ANA IgG muster<\/td><td><\/td><td>&nbsp;<\/td><td>Tuvastatud mustri kirjeldus (tabel 2, tabel 3)<\/td><\/tr><tr><td><\/td><td>ANA IgG tiiter<\/td><td><\/td><td><\/td><td>1:100; 1:320; 1:1000; &gt; 1:1000<\/td><\/tr><tr><td><\/td><td>S\u00fcsteemsete sidekoehaiguste IgG paneel<\/td><td>Negatiivne<\/td><td>&nbsp;<\/td><td>Positiivne<\/td><\/tr><tr><td><\/td><td>S\u00fcsteemse skleroosi IgG paneel<\/td><td>Negatiivne<\/td><td>&nbsp;<\/td><td>Positiivne<\/td><\/tr><tr><td><\/td><td>M\u00fcosiitide IgG paneel<\/td><td>Negatiivne<\/td><td>&nbsp;<\/td><td>Positiivne<\/td><\/tr><tr><td><\/td><td>Maksahaiguste IgG paneel<\/td><td>Negatiivne<\/td><td><\/td><td>Positiivne<\/td><\/tr><tr><td><\/td><td>dsDNA IgG QN<\/td><td>&lt; 10 kU\/L Negatiivne<\/td><td>10\u201315 kU\/L Piiripealne<\/td><td>&gt; 15 kU\/L Positiivne<\/td><\/tr><tr><td><\/td><td>Sm IgG QN<\/td><td>&lt; 7 kU\/L Negatiivne<\/td><td>7\u201310 kU\/L Piiripealne<\/td><td>&gt; 10 kU\/L Positiivne<\/td><\/tr><tr><td><\/td><td>U1RNP IgG QN<\/td><td>&lt; 5 kU\/L Negatiivne<\/td><td>5\u201310 kU\/L Piiripealne<\/td><td>&gt; 10 kU\/L Positiivne<\/td><\/tr><tr><td><\/td><td>SSA IgG QN<\/td><td>&lt; 7 kU\/L Negatiivne<\/td><td>7\u201310 kU\/L Piiripealne<\/td><td>&gt; 10 kU\/L Positiivne<\/td><\/tr><tr><td><\/td><td>SSB IgG QN<\/td><td>&lt; 7 kU\/L Negatiivne<\/td><td>7\u201310 kU\/L Piiripealne<\/td><td>&gt; 10 kU\/L Positiivne<\/td><\/tr><tr><td><\/td><td>Scl70 IgG QN<\/td><td>&lt; 7 kU\/L Negatiivne<\/td><td>7\u201310 kU\/L Piiripealne<\/td><td>&gt; 10 kU\/L Positiivne<\/td><\/tr><tr><td><\/td><td>Tsentromeer B IgG QN<\/td><td>&lt; 7 kU\/L Negatiivne<\/td><td>7\u201310 kU\/L Piiripealne<\/td><td>&gt; 10 kU\/L Positiivne<\/td><\/tr><tr><td><\/td><td>Jo1 IgG QN<\/td><td>&lt; 7 kU\/L Negatiivne<\/td><td>7\u201310 kU\/L Piiripealne<\/td><td>&gt; 10 kU\/L Positiivne<\/td><\/tr><tr><td><\/td><td>AMA M2 IgG QN<\/td><td>&lt; 4 kU\/L Negatiivne<\/td><td>4\u20136 kU\/L Piiripealne<\/td><td>&gt; 6 kU\/L Positiivne<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"has-medium-font-size wp-block-paragraph\"><strong>N\u00e4idustus ja kliiniline t\u00e4hendus<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">S\u00fcsteemsete sidekoehaiguste ja I t\u00fc\u00fcpi autoimmuunse hepatiidi diagnostika.<br>Kahtlus primaarsele biliaarsele kolangiidile (PBC; eriti negatiivse AMA korral).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Tabel 1<\/strong>. ANA IgG esinemissagedus<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table><tbody><tr><td width=\"1%\"><\/td><td width=\"60%\">S\u00fcsteemne er\u00fctematoosne luupus (SLE)<\/td><td width=\"39%\">95\u2013100%<\/td><\/tr><tr><td><\/td><td>Ravimindutseeritud luupus<\/td><td>100%<\/td><\/tr><tr><td><\/td><td>Sidekoehaiguse segavorm (MCTD)<\/td><td>100%<\/td><\/tr><tr><td><\/td><td>Reumatoidartriit (RA)<\/td><td>20\u201340%<\/td><\/tr><tr><td><\/td><td>Progresseeruv s\u00fcsteemne skleroos (SSc)<\/td><td>85\u201395%<\/td><\/tr><tr><td><\/td><td>Pol\u00fcm\u00fcosiit (PM) ja dermatom\u00fcosiit (DM)<\/td><td>30\u201350%<\/td><\/tr><tr><td><\/td><td>Sj\u00f6greni s\u00fcndroom (SjS)<\/td><td>70\u201380%<\/td><\/tr><tr><td><\/td><td>Haavandiline koliit<\/td><td>26%<\/td><\/tr><tr><td><\/td><td>Autoimmuunne hepatiit (AIH) (I t\u00fc\u00fcp)<\/td><td>100%<\/td><\/tr><tr><td><\/td><td><em>Sclerosis multiplex<\/em><\/td><td>25%<\/td><\/tr><tr><td><\/td><td>Kilpn\u00e4\u00e4rmehaigused<\/td><td>30\u201350%<\/td><\/tr><tr><td><\/td><td>Diskoidne luupus<\/td><td>5\u201325%<\/td><\/tr><tr><td><\/td><td>Isoleeritud antifosfolipiids\u00fcndroom<\/td><td>40\u201350%<\/td><\/tr><tr><td><\/td><td>Fibrom\u00fcalgia<\/td><td>15\u201325%<\/td><\/tr><tr><td><\/td><td>\u00dcldpopulatsioon (tiiter &gt; 1 : 100)<\/td><td>10%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Tabel 2.<\/strong> ANA IgG mustril p\u00f5hinev j\u00e4tku-uuringu valik<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table><tbody><tr><td width=\"1%\"><\/td><td width=\"20%\"><strong>ANA muster<\/strong><\/td><td width=\"20%\"><strong>Positiivne alates tiitrist<\/strong><\/td><td width=\"20%\"><strong>J\u00e4tku-uuringud<\/strong><\/td><td width=\"39%\"><strong>J\u00e4tku-uuring<\/strong><\/td><\/tr><tr><td><\/td><td>Homogeenne<\/td><td>1:100<\/td><td>Jah<\/td><td rowspan=\"3\">S\u00fcsteemsete sidekoehaiguste IgG paneel (IB)<\/td><\/tr><tr><td><\/td><td>Granulaarne<\/td><td>1:100<\/td><td>Jah<\/td><\/tr><tr><td><\/td><td>Tihe peengranulaarne<\/td><td>1:100<\/td><td>Jah<\/td><\/tr><tr><td><\/td><td>Tsentromeerne<\/td><td>1:100<\/td><td>Jah<\/td><td>Tsentromeer B IgG QN<\/td><\/tr><tr><td><\/td><td>Nukleaarsed t\u00e4pid (6-20)<\/td><td>1:100<\/td><td>Jah<\/td><td>Maksahaiguste IgG paneel (IB)<\/td><\/tr><tr><td><\/td><td>Nukleaarsed t\u00e4pid (2-6)<\/td><td>1:100<\/td><td>Ei<\/td><td>Puudub<\/td><\/tr><tr><td><\/td><td>Nukleolaarne<\/td><td>1:100<\/td><td>Jah<\/td><td>S\u00fcsteemse skleroosi IgG paneel (IB)<\/td><\/tr><tr><td><\/td><td>Tuumamembraan<\/td><td>1:100<\/td><td>Jah<\/td><td>Maksahaiguste IgG paneel (IB)<\/td><\/tr><tr><td><\/td><td>Scl-70\/Topo-I taoline<\/td><td>1:100<\/td><td>Jah<\/td><td>S\u00fcsteemse skleroosi IgG paneel (IB)<\/td><\/tr><tr><td><\/td><td>Mitootiline<\/td><td>1:1000<\/td><td>Ei<\/td><td>Puudub<\/td><\/tr><tr><td><\/td><td>Pleomorfne<\/td><td>1:100<\/td><td>Jah<\/td><td>S\u00fcsteemsete sidekoehaiguste IgG paneel (IB)<\/td><\/tr><tr><td><\/td><td>Klassifitseerimatu<\/td><td>1:320<\/td><td>Ei<\/td><td>Puudub<\/td><\/tr><tr><td><\/td><td>Ts\u00fctoplasmaatiline<\/td><td>1:100<\/td><td>Jah*<\/td><td>AMA M2 IgG QN v\u00f5i m\u00fcosiitide IgG paneel (IB)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">* Ts\u00fctoplasmaatilise ANA mustri tuvastamisel teostatakse j\u00e4tku-uuring ainult ts\u00fctoplasma retikulaarse mustri v\u00f5i (tiheda) peengranulaarse mustri korral.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Tabel 3.<\/strong> ANA IgG mustrid ICAP-i klassifikatsiooni ja ELM\u00dc \u00fchtlustatud vastusevormi alusel, neile vastavad sihtantigeenid ning seosed haiguste ja s\u00fcndroomidega.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table><tbody><tr><td width=\"1%\"><\/td><td width=\"20%\"><strong>ANA muster<\/strong><\/td><td width=\"40%\"><strong>Sihtantigeenid<\/strong><\/td><td width=\"39%\"><strong>Seos haigustega<\/strong><\/td><\/tr><tr><td><\/td><td>Homogeenne<\/td><td>dsDNA, nukleosoomid, histoonid<\/td><td>SLE, ravimindutseeritud luupus<\/td><\/tr><tr><td><\/td><td>Granulaarne<\/td><td>U1RNP, Sm, SSA, SSB, Mi2, Ku<\/td><td>MCTD, SLE, SjS, SSc, DM, SSc\/PM<\/td><\/tr><tr><td><\/td><td>Tihe peengranulaarne<\/td><td>DFS70<\/td><td>Harv (SjS, SSc, SLE)<\/td><\/tr><tr><td><\/td><td>Tsentromeerne<\/td><td>Tsentromeer A, tsentromeer B<\/td><td>SSc, PBC<\/td><\/tr><tr><td><\/td><td>Nukleaarsed t\u00e4pid (6-20)<\/td><td>Sp100, PML<\/td><td>PBC, s\u00fcsteemsed sidekoehaigused<\/td><\/tr><tr><td><\/td><td>Nukleaarsed t\u00e4pid (2-6)<\/td><td>&nbsp;<\/td><td>SjS, SLE<\/td><\/tr><tr><td><\/td><td>Nukleolaarne<\/td><td>PM\/Scl, Th\/To, RP11, RP155, fibrillariin, RNApol-I<\/td><td>SSc, PM\/DM<\/td><\/tr><tr><td><\/td><td>Tuumamembraan<\/td><td>Lamiin A, B, C, gp210, p62<\/td><td>PBC<\/td><\/tr><tr><td><\/td><td>Scl-70\/Topo-I taoline<\/td><td>&nbsp;<\/td><td>SSc<\/td><\/tr><tr><td><\/td><td>Mitootiline<\/td><td>K\u00e4\u00e4viniidid, tsentrosoomid<\/td><td>Harv (SSc, Raynaud fenomen, SLE, infektsioonid)<\/td><\/tr><tr><td><\/td><td>Pleomorfne<\/td><td>PCNA, tsentromeer F<\/td><td>SLE, pahaloomulised kasvajad<\/td><\/tr><tr><td><\/td><td>Ts\u00fctoplasmaatiline<\/td><td>AMA, Jo1, PL7, PL12, EJ, OJ, SRP, Rib-P<\/td><td>PBC, PM, SLE<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Koostaja: Anet Laanesoo<br>Uuendatud 30.09.2026<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Vt ka: <a href=\"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/autoimmuunuuringud\/susteemsete-sidekoehaigustega-seotud-igg-paneel\/\">S\u00fcsteemsete sidekoehaigustega seotud IgG paneel<\/a><br><a href=\"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/autoimmuunuuringud\/susteemse-skleroosiga-seotud-igg-paneel\/\">S\u00fcsteemse skleroosiga seotud IgG paneel<\/a><br><a href=\"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/autoimmuunuuringud\/autoimmuunsete-muosiitidega-seotud-igg-paneel\/\">Autoimmuunsete m\u00fcosiitidega seotud IgG paneel<\/a><br><a href=\"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/autoimmuunuuringud\/maksahaiguste-igg-paneel-ib\/\">Maksahaiguste IgG paneel<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Immuunanal\u00fc\u00fcsi osakond Anal\u00fc\u00fcsid: ANA IgG (IIF) ANA IgG muster ANA IgG tiiter S\u00fcsteemsete sidekoehaiguste IgG paneel (IB) S\u00fcsteemse skleroosi IgG paneel (IB) M\u00fcosiitide IgG paneel (IB) Maksahaiguste IgG paneel (IB) dsDNA IgG QN Sm IgG QN U1RNP IgG QN SSA\/Ro IgG QN SSB\/La IgG QN Scl70 IgG QN Tsentromeer B IgG QN Jo1 IgG QN [&hellip;]<\/p>\n","protected":false},"author":38,"featured_media":0,"parent":7253,"menu_order":16,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_uag_custom_page_level_css":"","footnotes":""},"class_list":["post-11458","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tuumavastase IgG (ANA IgG) paneel (IIF) - \u00dchendlabor<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/autoimmuunuuringud\/susteemsete-sidekoehaiguste-uuringud\/\" \/>\n<meta property=\"og:locale\" content=\"et_EE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tuumavastase IgG (ANA IgG) paneel (IIF) - \u00dchendlabor\" \/>\n<meta property=\"og:description\" content=\"Immuunanal\u00fc\u00fcsi osakond Anal\u00fc\u00fcsid: ANA IgG (IIF) ANA IgG muster ANA IgG tiiter S\u00fcsteemsete sidekoehaiguste IgG paneel (IB) S\u00fcsteemse skleroosi IgG paneel (IB) M\u00fcosiitide IgG paneel (IB) Maksahaiguste IgG paneel (IB) dsDNA IgG QN Sm IgG QN U1RNP IgG QN SSA\/Ro IgG QN SSB\/La IgG QN Scl70 IgG QN Tsentromeer B IgG QN Jo1 IgG QN [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/autoimmuunuuringud\/susteemsete-sidekoehaiguste-uuringud\/\" \/>\n<meta property=\"og:site_name\" content=\"\u00dchendlabor\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-08T11:01:32+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Eeldatav lugemisaeg\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/autoimmuunuuringud\\\/susteemsete-sidekoehaiguste-uuringud\\\/\",\"url\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/autoimmuunuuringud\\\/susteemsete-sidekoehaiguste-uuringud\\\/\",\"name\":\"Tuumavastase IgG (ANA IgG) paneel (IIF) - \u00dchendlabor\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/#website\"},\"datePublished\":\"2025-05-26T16:28:08+00:00\",\"dateModified\":\"2026-10-08T11:01:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/autoimmuunuuringud\\\/susteemsete-sidekoehaiguste-uuringud\\\/#breadcrumb\"},\"inLanguage\":\"et\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/autoimmuunuuringud\\\/susteemsete-sidekoehaiguste-uuringud\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/autoimmuunuuringud\\\/susteemsete-sidekoehaiguste-uuringud\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"K\u00e4siraamat\",\"item\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Autoimmuunuuringud\",\"item\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/autoimmuunuuringud\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Tuumavastase IgG (ANA IgG) paneel (IIF)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/#website\",\"url\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/\",\"name\":\"\u00dchendlabor\",\"description\":\"Hoolivus, Uuendusmeelsus, P\u00e4devus ja Usaldusv\u00e4\u00e4rsus\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"et\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tuumavastase IgG (ANA IgG) paneel (IIF) - \u00dchendlabor","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/autoimmuunuuringud\/susteemsete-sidekoehaiguste-uuringud\/","og_locale":"et_EE","og_type":"article","og_title":"Tuumavastase IgG (ANA IgG) paneel (IIF) - \u00dchendlabor","og_description":"Immuunanal\u00fc\u00fcsi osakond Anal\u00fc\u00fcsid: ANA IgG (IIF) ANA IgG muster ANA IgG tiiter S\u00fcsteemsete sidekoehaiguste IgG paneel (IB) S\u00fcsteemse skleroosi IgG paneel (IB) M\u00fcosiitide IgG paneel (IB) Maksahaiguste IgG paneel (IB) dsDNA IgG QN Sm IgG QN U1RNP IgG QN SSA\/Ro IgG QN SSB\/La IgG QN Scl70 IgG QN Tsentromeer B IgG QN Jo1 IgG QN [&hellip;]","og_url":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/autoimmuunuuringud\/susteemsete-sidekoehaiguste-uuringud\/","og_site_name":"\u00dchendlabor","article_modified_time":"2026-10-08T11:01:32+00:00","twitter_card":"summary_large_image","twitter_misc":{"Eeldatav lugemisaeg":"6 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/autoimmuunuuringud\/susteemsete-sidekoehaiguste-uuringud\/","url":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/autoimmuunuuringud\/susteemsete-sidekoehaiguste-uuringud\/","name":"Tuumavastase IgG (ANA IgG) paneel (IIF) - \u00dchendlabor","isPartOf":{"@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/#website"},"datePublished":"2025-05-26T16:28:08+00:00","dateModified":"2026-10-08T11:01:32+00:00","breadcrumb":{"@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/autoimmuunuuringud\/susteemsete-sidekoehaiguste-uuringud\/#breadcrumb"},"inLanguage":"et","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/autoimmuunuuringud\/susteemsete-sidekoehaiguste-uuringud\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/autoimmuunuuringud\/susteemsete-sidekoehaiguste-uuringud\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.kliinikum.ee\/yhendlabor\/"},{"@type":"ListItem","position":2,"name":"K\u00e4siraamat","item":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/"},{"@type":"ListItem","position":3,"name":"Autoimmuunuuringud","item":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/autoimmuunuuringud\/"},{"@type":"ListItem","position":4,"name":"Tuumavastase IgG (ANA IgG) paneel (IIF)"}]},{"@type":"WebSite","@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/#website","url":"https:\/\/www.kliinikum.ee\/yhendlabor\/","name":"\u00dchendlabor","description":"Hoolivus, Uuendusmeelsus, P\u00e4devus ja Usaldusv\u00e4\u00e4rsus","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.kliinikum.ee\/yhendlabor\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"et"}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false},"uagb_author_info":{"display_name":"Kadi Siigur","author_link":"https:\/\/www.kliinikum.ee\/yhendlabor\/author\/kadisi\/"},"uagb_comment_info":0,"uagb_excerpt":"Immuunanal\u00fc\u00fcsi osakond Anal\u00fc\u00fcsid: ANA IgG (IIF) ANA IgG muster ANA IgG tiiter S\u00fcsteemsete sidekoehaiguste IgG paneel (IB) S\u00fcsteemse skleroosi IgG paneel (IB) M\u00fcosiitide IgG paneel (IB) Maksahaiguste IgG paneel (IB) dsDNA IgG QN Sm IgG QN U1RNP IgG QN SSA\/Ro IgG QN SSB\/La IgG QN Scl70 IgG QN Tsentromeer B IgG QN Jo1 IgG QN&hellip;","_links":{"self":[{"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/pages\/11458","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/comments?post=11458"}],"version-history":[{"count":9,"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/pages\/11458\/revisions"}],"predecessor-version":[{"id":19940,"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/pages\/11458\/revisions\/19940"}],"up":[{"embeddable":true,"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/pages\/7253"}],"wp:attachment":[{"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/media?parent=11458"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}